Neurogene Stock Jumps 37% On FDA Backing For Rett Syndrome Gene Therapy Trial

(RTTNews) - Neurogene Inc. (NGNE) surged 37.37 percent to $20.54 after announcing it has secured a written agreement with the FDA on the design of Embolden, its registrational trial of NGN-401 gene therapy for treating females aged 3 and older with Rett syndrome. The stock opened at $15.50, traded as high as $19.73 on the Nasdaq, and saw volume of 312,878 shares, exceeding its average of 253,309, as investors responded positively to the regulatory milestone. The study aims to deliver a potential life-changing treatment for this devastating rare neurological disorder.